FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only ...

As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...

GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...

Many patients with severe gastroparesis unfortunately do not achieve adequate relief from the previously outlined therapies. In such cases, consideration should be given to implantation of a ...

(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, underscores its ...

Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the only US FDA-approved medication for the treatment of gastroparesis. However, the FDA ...

Evoke Pharma (EVOK) underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA’s recent update ...

Undiagnosed or untreated EPI could result in muscle loss since the patient isn’t absorbing the necessary nutrients.